Conducting radiogenomic research - Do not forget careful consideration of the clinical data

Christian Nicolaj Andreassen; Gillian C. Barnett; Johannes A. Langendijk; Jan Alsner; Dirk De Ruysscher; Mechtild Krause; Soren M. Bentzen; Joanne S. Haviland; Clare Griffin; Philip Poortmans; John R. Yarnold

doi:10.1016/j.radonc.2012.11.004

Conducting radiogenomic research - Do not forget careful consideration of the clinical data

Christian Nicolaj Andreassen^*, Gillian C. Barnett, Johannes A. Langendijk, Jan Alsner, Dirk De Ruysscher, Mechtild Krause, Soren M. Bentzen, Joanne S. Haviland, Clare Griffin, Philip Poortmans, John R. Yarnold

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The field of radiogenomics has evolved substantially over the last few years. Cooperative research groups have been established and high throughput genotyping has become increasingly feasible and affordable. Nevertheless, a number of clinical and dosimetric issues need to be carefully considered in order to fully exploit these new possibilities.

Original language	English
Pages (from-to)	337-340
Journal	Radiotherapy and Oncology
Volume	105
Issue number	3
DOIs	https://doi.org/10.1016/j.radonc.2012.11.004
Publication status	Published - Dec 2012

Keywords

Normal tissue radiosensitivity
Predictive markers
Single nucleotide polymorphisms

Access to Document

10.1016/j.radonc.2012.11.004

Cite this

@article{8c68d3c1dc3b418fba9a09ef7273e804,

title = "Conducting radiogenomic research - Do not forget careful consideration of the clinical data",

abstract = "The field of radiogenomics has evolved substantially over the last few years. Cooperative research groups have been established and high throughput genotyping has become increasingly feasible and affordable. Nevertheless, a number of clinical and dosimetric issues need to be carefully considered in order to fully exploit these new possibilities.",

keywords = "Normal tissue radiosensitivity, Predictive markers, Single nucleotide polymorphisms",

author = "Andreassen, {Christian Nicolaj} and Barnett, {Gillian C.} and Langendijk, {Johannes A.} and Jan Alsner and {De Ruysscher}, Dirk and Mechtild Krause and Bentzen, {Soren M.} and Haviland, {Joanne S.} and Clare Griffin and Philip Poortmans and Yarnold, {John R.}",

year = "2012",

month = dec,

doi = "10.1016/j.radonc.2012.11.004",

language = "English",

volume = "105",

pages = "337--340",

journal = "Radiotherapy and Oncology",

issn = "0167-8140",

publisher = "Elsevier Ireland Ltd",

number = "3",

}

TY - JOUR

T1 - Conducting radiogenomic research - Do not forget careful consideration of the clinical data

AU - Andreassen, Christian Nicolaj

AU - Barnett, Gillian C.

AU - Langendijk, Johannes A.

AU - Alsner, Jan

AU - De Ruysscher, Dirk

AU - Krause, Mechtild

AU - Bentzen, Soren M.

AU - Haviland, Joanne S.

AU - Griffin, Clare

AU - Poortmans, Philip

AU - Yarnold, John R.

PY - 2012/12

Y1 - 2012/12

N2 - The field of radiogenomics has evolved substantially over the last few years. Cooperative research groups have been established and high throughput genotyping has become increasingly feasible and affordable. Nevertheless, a number of clinical and dosimetric issues need to be carefully considered in order to fully exploit these new possibilities.

AB - The field of radiogenomics has evolved substantially over the last few years. Cooperative research groups have been established and high throughput genotyping has become increasingly feasible and affordable. Nevertheless, a number of clinical and dosimetric issues need to be carefully considered in order to fully exploit these new possibilities.

KW - Normal tissue radiosensitivity

KW - Predictive markers

KW - Single nucleotide polymorphisms

U2 - 10.1016/j.radonc.2012.11.004

DO - 10.1016/j.radonc.2012.11.004

M3 - Article

C2 - 23245646

SN - 0167-8140

VL - 105

SP - 337

EP - 340

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

IS - 3

ER -